Refine by
Diabetic Ulcer Articles & Analysis
30 news found
Bremen, Germany – May 4, 2026 — Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at EWMA-DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany.This year EWMA, The European Wound Management Association meeting, is held in ...
ByKerecis
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...
Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, ...
"One of the repercussions of COVID-19 is its impact on men's sexual health. COVID-19 infection is expected to be associated with an increased likelihood of erectile dysfunction (ED). Considering the high transmissibility of COVID-19, ED could be a concerning consequence for a large segment of the population" https://www.ncbi.nim.nih.gov/pmc/articles/PMC8450276/. Coincidentally, DirexGroup ...
SOMERVILLE, Mass., March 24, 2022 — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced a $45 million Series C round led by D1 Capital Partners, along with two new investors, the Medtech Convergence Fund and an undisclosed strategic investor. Existing ...
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have ...
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the ...
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business Development, Health Economics, Marketing & Communication and ...
Advanced Oxygen Therapy Inc. (AOTI), the leader in noninvasive sustained wound healing solutions, announced today a number of significant additions to its Leadership Team, bringing to the company over 100 years of combined strategic experience: Chief Medical Officer – Dr. Matthew G. Garoufalis is Co-Chair of the Alliance of Wound Care Stakeholders and past President of both the American ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic ...
SOMERVILLE, Mass., January 18, 2022 — Podimetrics, a virtual care support company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which compared the health of individuals during and after periods of diabetic foot ulceration — open sores or wounds on the foot, which commonly occur among those with diabetes and are the ...
PHILADELPHIA and SOMERVILLE, Mass., October 26, 2021 — Independence Blue Cross (Independence) and Podimetrics, a virtual care management company dedicated to preventing diabetic amputations, today announced an agreement for Podimetrics to remotely monitor Independence fully insured commercial members who have diabetes and a history of a diabetic foot ulcer with the use of the ...
Advanced Oxygen Therapy Inc. (AOTI) announced today that its unique multimodality Topical Wound Oxygen (TWO2) therapy was recently highlighted at multiple leading international clinical conferences across the United States and United Kingdom. AOTI participated both as a sponsor and exhibitor at these events that were conducted in a hybrid format, where attendance could be either in person, or ...
VA Innovation Ecosystem leader recognized for the Initiative to End Diabetic Limb Loss. SOMERVILLE, Mass., June 29, 2021 — Podimetrics, a virtual care management company dedicated to preventing costly and deadly diabetic amputations, congratulates Suzanne Shirley today on winning the Service to Citizen Award in recognition for her leadership and dedication to the Veteran population ...
Advanced Oxygen Therapy Inc. (AOTI) today announced that 2,000,000 treatments of its unique cyclical-pressure Topical Wound Oxygen (TWO2) therapy have now been applied by patients safely at home. Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and ...
Reamputation Rates Have Not Improved Over Two Decades. SOMERVILLE, Mass., June 10, 2021 — Podimetrics, a virtual care management company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which found patients with diabetes who have an amputation have a 37 percent chance of having reamputation within five years. The ...
Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose cohort. The primary endpoint of this dose escalation ...
On 27 May 2021 Aposcience AG received the notification of the Paul-Ehrlich-Institut of the approval of the clinical phase II trial in diabetic foot ulcer (DFU), MARSYAS II, for Germany. Currently, the MARSYAS II trial has regulatory approvals for Austria, Czech Republic, Germany and Poland. ...
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for focused, shockwave systems in the non-medical field today presented results from a clinical case series that demonstrated improved wound healing when treated with its FDA-cleared, ...